Literature DB >> 12667274

Cystic fibrosis: current trends in respiratory care.

Jeffrey S Wagener1, Aree A Headley.   

Abstract

Cystic fibrosis is a genetic disease that typically produces malnutrition and chronic respiratory infections. Prolonged bronchial obstruction, infection, and inflammation result in bronchiectstasis and permanent lung damage. Most cystic fibrosis patients die because of this progressive respiratory disease. Thus, in the absence of a cure, effective respiratory therapy is the primary means to extend and improve the quality of life for the cystic fibrosis patient. Aerosol therapy, airway clearance techniques, and noninvasive ventilation can all improve quality of life and possibly extend survival. Close patient monitoring with pulmonary function testing, chest radiography, and induced sputum can result in earlier treatment, potentially reducing permanent lung damage. Earlier diagnosis has prevented serious complications through early initiation of preventive therapies such as improved nutrition. Copyright 2003 Daedalus Enterprises

Entities:  

Mesh:

Year:  2003        PMID: 12667274

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

Review 1.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Zbys Fedorowicz; Vidhu Thaker; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2015-01-18

2.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Vidhu Thaker; Anne B Chang; Amy I Price
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

Review 3.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Vidhu Thaker; Anne B Chang; Amy I Price
Journal:  Cochrane Database Syst Rev       Date:  2017-08-22

4.  Chest associated to motor physiotherapy improves cardiovascular variables in newborns with respiratory distress syndrome.

Authors:  Luiz Carlos de Abreu; Vitor E Valenti; Adriana G de Oliveira; Claudio Leone; Arnaldo Af Siqueira; Dafne Herreiro; Rubens Wajnsztejn; Katia V Manhabusque; Hugo Macedo Júnior; Carlos B de Mello Monteiro; Laís L Fernandes; Paulo Hn Saldiva
Journal:  Int Arch Med       Date:  2011-10-26

5.  Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  Marie-Sophie Brochet; Anne-Cathrine McDuff; Jean-François Bussières; Elaine Caron; Geneviève Fortin; Denis Lebel; Jacques-Edouard Marcotte
Journal:  Can Respir J       Date:  2007 Nov-Dec       Impact factor: 2.409

6.  Benefit of educational feedback for the use of positive expiratory pressure device.

Authors:  Gregory Reychler; Manon Jacquemart; William Poncin; Anne-Sophie Aubriot; Giuseppe Liistro
Journal:  Braz J Phys Ther       Date:  2015-09-01       Impact factor: 3.377

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.